Research progress on the efficacy of brigatinib/brigatinib (Embry) combined with Erbitux

In the context of continuous updates in the treatment of lung cancer, the combined research of Brigatinib/Cetuximab (Cetuximab) has gradually become a hot topic. Erbitux, as an EGFR monoclonal antibody drug, is mainly used in colorectal cancer and head and neck squamous cell carcinoma. However, in recent years, researchers have found that its combination with ALK inhibitors is expected to open up new paths in drug-resistant environments. Drug resistance is a core problem in the treatment of ALK-positive non-small cell lung cancer. As patients receive first- or second-generation ALK inhibitors, mutations and bypass activation signals can cause tumor cells to escape the inhibitory effect of a single target. At this time, a strategy to jointly block the ALK and EGFR pathways was proposed.

Brigatinib has shown strong ability to overcome the ALK resistance mechanism, especially in key mutations such as G1202R. However, some patients are still resistant to it. Overseas studies have pointed out that some drug resistance is related to abnormal activation of the EGFR pathway, which provides a theoretical basis for the combination of brigatinib and Erbitux. Preclinical experiments have shown that this combination can produce a more obvious inhibitory effect on some drug-resistant cell lines, suggesting that under a specific molecular background, dual-pathway blockade may enhance the therapeutic effect.

In the clinical exploration phase, small-scale studies have begun to observe the safety and potential efficacy of brigatinib combined with Erbitux. Although current data are still limited and large-scale phase III evidence has not yet been formed, some researchers have reported improvements in disease control rates and the possibility of delaying drug resistance. This type of research provides a more selective framework for future individualized treatments.

It is worth emphasizing that combination therapy inevitably brings the risk of drug interactions and adverse reactions, so tolerance management has become a core focus of research. At present, the international oncology community generally believes that this strategy is still in the exploratory stage, but with the refinement of molecular testing, the combination program may be applied to those special groups with both ALK mutations and EGFR pathway activation.

Reference materials:https://www.alunbrig.com/